Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna (MRNA) remains at the forefront of mRNA technology innovation, developing transformative therapies for infectious diseases, oncology, and rare conditions. This dedicated news hub provides investors and healthcare professionals with essential updates directly from the company and verified sources.
Access official press releases covering clinical trial results, regulatory milestones, and strategic partnerships, alongside analysis of quarterly earnings and pipeline developments. Our curated collection ensures you stay informed about Moderna's progress in advancing mRNA-based medicines without promotional bias.
Key updates include developments in respiratory vaccines, cancer immunotherapy candidates, and rare disease treatments. Bookmark this page for real-time access to Moderna's verified announcements and objective reporting on one of biotechnology's most innovative platforms.
Moderna announced interim results from its Phase 3 trial of mRNA-1010, a seasonal influenza vaccine candidate. The trial showed superiority in seroconversion rates for A/H3N2 and A/H1N1 strains and non-inferiority for A/H1N1 geometric mean titer ratios. However, non-inferiority was not met for the influenza B strains. The vaccine was well-tolerated, with a reported 70% of recipients experiencing minor adverse reactions. The ongoing efficacy study has recorded over 200 PCR-confirmed cases, primarily of influenza A. An interim analysis is expected by the end of Q1 2023. mRNA-1010 is one of five influenza candidates being evaluated by Moderna.
Personalis, Inc. (PSNL) and Moderna, Inc. (MRNA) have signed a new agreement to utilize the Personalis NeXT Platform for clinical studies involving the investigational personalized cancer vaccine, mRNA-4157/V940. This platform previously supported the Phase 2b clinical study, sequencing genomic data from patient tumor samples to identify mutations that may prompt tailored antitumor responses. Chris Hall from Personalis expressed excitement about continuing their collaboration with Moderna, emphasizing the aim to advance individualized cancer treatments.
Moderna, Inc. (NASDAQ:MRNA) will host a live conference call and webcast on February 23, 2023, at 8:00 a.m. ET to report its fourth quarter and full year 2022 financial results.
The call will provide a corporate update, and a webcast will be available in the Investors section of the Moderna website.
Since its inception, Moderna has evolved from a research-stage company to a major biotechnology enterprise with a diverse clinical portfolio, strong manufacturing capabilities, and significant mRNA technology advancements.
Moderna, Inc. (NASDAQ:MRNA) announced that its investigational mRNA vaccine candidate, mRNA-1345, for respiratory syncytial virus (RSV) has received Breakthrough Therapy Designation from the FDA. This designation is granted based on the positive topline data showing an efficacy of 83.7% against RSV lower respiratory tract disease in adults aged 60 and older, as observed in the ConquerRSV Phase 3 trial. The vaccine was well tolerated, with mild side effects reported. Moderna plans to submit a licensing application in the first half of 2023, aiming to address the significant health impact of RSV in older adults.
Moderna's mRNA-1345 has shown a vaccine efficacy of 83.7% against RSV lower respiratory tract disease in adults over 60, based on results from the Phase 3 ConquerRSV trial with 37,000 participants across 22 countries. The Data and Safety Monitoring Board (DSMB) found no safety concerns, indicating the vaccine was well-tolerated. Moderna plans to seek regulatory approval in the first half of 2023. This marks a significant step in addressing the public health burden of RSV, which significantly affects older adults, leading to thousands of hospitalizations each year. Further detailed results are expected to be presented at an upcoming conference.
Moderna reported unaudited COVID-19 vaccine sales of approximately $18.4 billion for 2022, expecting a minimum of $5.0 billion in 2023 from confirmed contracts. The company has 48 programs in development, including 36 in clinical trials, and plans to increase R&D investment to $4.5 billion for 2023. Key updates include advancing RSV and flu vaccine trials, a promising cancer treatment in collaboration with Merck, and ongoing studies for rare diseases, including propionic acidemia. Moderna's strong cash position exceeds $18 billion.
Moderna and CytomX have announced a collaboration to develop mRNA-based conditionally activated therapies. CytomX will receive an upfront payment of $35 million, including $5 million in research funding, and could earn up to $1.2 billion in milestone payments. This partnership aims to leverage Moderna's mRNA technology and CytomX's Probody platform to create innovative therapeutics for oncology and beyond. Moderna will lead clinical development, while CytomX retains rights to royalties on net sales of commercialized products.
Moderna, Inc. (NASDAQ:MRNA) has announced its acquisition of OriCiro Genomics K.K. for $85 million. This strategic move aims to enhance Moderna's capabilities in mRNA therapeutics by integrating OriCiro's advanced cell-free DNA synthesis technologies. CEO Stéphane Bancel highlighted that the acquisition will significantly bolster their manufacturing processes and R&D efforts. OriCiro's leadership expressed confidence in the synergy between both companies, which is expected to accelerate the development of innovative therapeutics. The acquisition is viewed as a pivotal step in expanding Moderna's technological portfolio.
Moderna, Inc. (NASDAQ:MRNA) will have CEO Stéphane Bancel present its mRNA pipeline updates at the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023, at 5:15 p.m. ET. Attendees can watch the live webcast on Moderna's investors website, where a recording will also be available for 30 days post-event. Founded a decade ago, Moderna has shifted from a research-focused entity to a leading biotechnology firm with a diverse portfolio in therapeutics and vaccines, including significant contributions to COVID-19 vaccine development.
Moderna has finalized a strategic partnership with the UK government to establish a cutting-edge mRNA research, development, and manufacturing facility, enhancing UK capabilities for pandemic response. This ten-year collaboration aims to make domestically manufactured mRNA respiratory vaccines available, contingent upon regulatory approval. Construction of the Moderna Innovation and Technology Centre is expected to begin in early 2023, with operations starting by 2025. The facility will support the UK's 100 Days Mission to better manage future pandemics.
FAQ
What is the current stock price of Moderna (MRNA)?
What is the market cap of Moderna (MRNA)?
